Global Adrenoleukodystrophy Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Adrenoleukodystrophy Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namelyDietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
Adrenoleukodystrophy Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Adrenoleukodystrophy Drugs market is projected to reach US$ 960 million in 2034, increasing from US$ 337.8 million in 2022, with the CAGR of 15.9% during the period of 2024 to 2034. Demand from Childhood Cerebral ALD and Adrenomyeloneuropathy (AMN) are the major drivers for the industry.
By region, North America has the highest share of revenue, exceeding 60 percent in 2019.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Adrenoleukodystrophy Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bluebird Bio Inc
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals
Segment by Type
Hormone Replacement
Transplant
Others
Childhood Cerebral ALD
Adrenomyeloneuropathy (AMN)
Addison-only
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Adrenoleukodystrophy Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Adrenoleukodystrophy Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Adrenoleukodystrophy Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Adrenoleukodystrophy Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Adrenoleukodystrophy Drugs introduction, etc. Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Adrenoleukodystrophy Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namelyDietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
Adrenoleukodystrophy Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Adrenoleukodystrophy Drugs market is projected to reach US$ 960 million in 2034, increasing from US$ 337.8 million in 2022, with the CAGR of 15.9% during the period of 2024 to 2034. Demand from Childhood Cerebral ALD and Adrenomyeloneuropathy (AMN) are the major drivers for the industry.
By region, North America has the highest share of revenue, exceeding 60 percent in 2019.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Adrenoleukodystrophy Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bluebird Bio Inc
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals
Segment by Type
Hormone Replacement
Transplant
Others
Segment by Application
Childhood Cerebral ALD
Adrenomyeloneuropathy (AMN)
Addison-only
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Adrenoleukodystrophy Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Adrenoleukodystrophy Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Adrenoleukodystrophy Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Adrenoleukodystrophy Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Adrenoleukodystrophy Drugs introduction, etc. Adrenoleukodystrophy Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Adrenoleukodystrophy Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices